NEWS

Each year at the Annual Meeting of The American Society of Hematology (ASH), there are more MPN research and clinical trial reports. This year, some unique highlights include 16 topics we find notable, along with many others with a potential connection to MPNs.  Artificial intelligence (AI) to differentiate between essential thrombocythemia and prefibrotic primary myelofibrosis. … Read More »MPN News to Expect at ASH 2023

Thrive Award Spotlight : Idoroenyi Amanam, MD Using our own immune system to treat cancers has become a reality for many solid and blood cancers. “It’s an ideal therapy, as it’s our own specialized system that helps treat abnormal cells,” according to Idoroenyi Amanam, MD, of City of Hope. For MPNs, there is a need… Read More »Investigation of IL-1RAP in Myeloproliferative Neoplasms: Potential Novel Anti-leukemic Therapy

An MPNRF Patient Impact Council recently launched to actively advocate for the patient voice and perspective in all aspects of our work to promote research advances and therapies with meaningful patient benefits.    Created with very clear objectives and activities, the council includes individuals representing diversity in MPN experiences, diagnosis, skills, community connections, geographic locations, and… Read More »2024-2026 Patient Impact Council Announced

Thrive Award Spotlight : Iannis Aifantis, PhD “Our work has previously focused on other types of blood cancer, including myeloid and lymphoid leukemias,” says Iannis Aifantis, PhD, of NYU Langone. “A key aspect of the pathogenesis of myelofibrosis (MF) is the abnormal creation of blood outside the bone marrow,” for instance in the spleen. “Our… Read More »Dissecting and Targeting Transcriptional and Epigenetic Regulation in Advanced Myelofibrosis

As of November 6th, 2023, the MPN Research Foundation has opened the MPN Challenge funding cycle. Please click here for further details on eligibility, proposal guidelines, and deadlines. Proposals are due January 30th, 2024.   

MPN Research Foundation is pleased to share the news of the US FDA approval of momelotinib for the treatment of myelofibrosis patients with anemia whether they have had prior treatment or not. Let’s break down what the approval of this new drug means for those impacted by MPNs: • Treatment options are expanding. Janus kinase (JAK) inhibitors… Read More »What to Know About the FDA Approval of momelotinib

“From the outset, we recognized that outstanding care of MPN patients required not just hematologists (who would be their primary doctors) but also the participation of other specialists who had expertise in the complications of MPNs, such as cardiologists, neurologists, vascular surgeons, interventional radiologists, dermatologists, infectious disease specialists, gastroenterologists, and rheumatologists.”         … Read More »Q&A with MPN Pioneer Andrew Schafer, MD

Philadelphia-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematologic malignancies characterized by the abnormal proliferation of blood cells in the bone marrow. MPNs cause significant morbidity in the form of burdensome symptoms, potentially fatal cardiovascular complications, progression to more aggressive disease, and over time, can evolve to… Read More »Current and Emerging Therapies

Dr. Ruben Mesa on his move to Wake Forest Baptist Comprehensive Cancer Center MPN patients are asking about your recent move from MD Anderson to Levine Cancer Center/Wake Forest Health. How would you describe the impact of your move?   I am excited to be joining two wonderful MPN teams already well established – in Charlotte… Read More »Q&A with Dr. Ruben Mesa

Just Published NUTRIENT Trial: Mediterranean Diet Intervention in MPNs The Mediterranean diet has long been associated with disease fighting anti-inflammatory benefits. In recent years, it has become a standard component of care for the prevention and management of many chronic conditions, such as cardiovascular disease. It has not yet entered the treatment algorithm for MPNs,… Read More »Just Published NUTRIENT Trial: Mediterranean Diet Intervention in MPNs